[medical citation needed]
| Verifiedfields | changed |
|---|---|
| Verifiedrevid | 462265233 |
| Tradename | Dipentum |
| Medlineplus | a601088 |
| Dailymedid | Olsalazine |
| Pregnancy au | C |
| Pregnancy au comment | [1] |
| Pregnancy us | C |
| Pregnancy us comment | [1] |
| Legal au | S4 |
| Legal uk | POM |
| Legal us | Rx-only |
| Routes of administration | By mouth |
| Atc prefix | A07 |
| Atc suffix | EC03 |
| Protein bound | 99% |
| Elimination half-life | 0.9 hours |
| Iupac name | 5,5'-diazenediyldi(2-hydroxybenzoic acid) |
| Index2 label | as salt |
| Cas number | 15722-48-2 |
| Pubchem | 22419 |
| Drugbank | DB01250 |
| Chemspiderid | 10642377 |
| Unii | ULS5I8J03O |
| Kegg | D08295 |
| Kegg 2 | D00727 |
| Chembl | 425 |
| C | 14 |
| H | 10 |
| N | 2 |
| O | 6 |
| Smiles | O=C(O)c1cc(ccc1O)/N=N/c2cc(C(O)=O)c(O)cc2 |
| Stdinchi | 1S/C14H10N2O6/c17-11-3-1-7(5-9(11)13(19)20)15-16-8-2-4-12(18)10(6-8)14(21)22/h1-6,17-18H,(H,19,20)(H,21,22)/b16-15+ |
| Stdinchikey | QQBDLJCYGRGAKP-FOCLMDBBSA-N |
Olsalazine is an anti-inflammatory medication used in the treatment of ulcerative colitis.[2][3] It is sold under the brand name Dipentum.[4]
Olsalazine itself is a prodrug of mesalazine (5-aminosalicyclic acid or 5-ASA) and is not absorbed in the small intestine. Instead it continues through to the colon where it is cleaved into two molecules of 5-ASA by azoreductases produced by colonic bacteria. Olsalazine thus exerts its anti-inflammatory effect by its colonic breakdown into 5-ASA which inhibits cyclooxygenase and lipoxygenase thereby reducing prostaglandin and leukotriene production.[4]
History
Olsalazine gained Food and Drug Administration (FDA) approval in 1990.
Supply
The drug is supplied by UCB Pharma.
Research
In 2006 the Australian biotech company Giaconda received a European patent for a combination therapy for treating constipation-predominant irritable bowel syndrome that uses olsalazine and the anti-gout drug colchicine, for trials the following year.[5]
References
- ^ "Olsalazine (Dipentum) Use During Pregnancy". Drugs.com. 6 September 2019. Retrieved 9 October 2020.
- ^ "Olsalazine--a further choice in ulcerative colitis". Drug and Therapeutics Bulletin. 28 (15): 57–8. July 1990. doi:10.1136/dtb.28.15.57. PMID 2131213. S2CID 7178709
- ^ Wadworth AN, Fitton A (April 1991). "Olsalazine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in inflammatory bowel disease". Drugs. 41 (4): 647–64. doi:10.2165/00003495-199141040-00009. PMID 1711964. S2CID 243654426
- ^ "Olsalazine Sodium 250 mg Capsules - Summary of Product Characteristics (SmPC) - (emc)". www.medicines.org.uk. Retrieved 9 January 2021.
- ^ "Giaconda gets European patent for drug". The Sydney Morning Herald. 28 December 2006. Retrieved 16 January 2021.